JPRN-UMIN000038871已完成未知
Efficacy trial of 4 weeks ingestion of the development code MSHF001 food - Efficacy trial of 4 weeks ingestion of the development code MSHF001 food
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 入组人数
- 100
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 59years-old(—)
- 性别
- Female
入选标准
- 未提供
排除标准
- •-Subjects with systemic illness. -Subjects who are diagnosed as menopausal disorders. -Subjects who are under Hormone Replacement Therapy, HRT, and/or medication which would affect blood hormone levels. -Subjects who are outpatients or were treated by doctor within a month. -Subjects who regularly take medicine. -Subjects who regularly take medicines that affect menopausal symptoms. -Subjects who are pregnant or lactating, or planned to become pregnant in the near future. -Subjects with smoking habit. -Subjects with drinking habit in 5 or more days a week. -Subjects who have possibilities for emerging allergy to foods, metals, and drugs. -Subjects with illnesses or diseases on their face, especially such as atopic dermatitis, or psoriasis, or severe acne. -Subjects who habitually having specific polyphenol-rich health food and drink. -Subjects with high anxiety questionnaire values. -Subjects with high Kupperman Kohnenki Shohgai Index. -Subjects who easily have skin rashes. -Subjects with potential conflict of interest.
研究者
相似试验
已完成
不适用
Efficacy trial of 4 weeks ingestion of the development code MSHF001JPRN-UMIN000033191Kao Corporation20
已完成
不适用
4-Week Study of 'MYP/MYPlus' Natural Extract for Improving COVID-19 Related FatigueSymptoms, signs and abnormal clinical and laboratory findings, NECKCT0008948Daejeon Korean Medicine Hospital of Daejeon University100
已完成
2 期
Dosefinding trial studying effect of 4 weeks Intervention on safety and efficacy in males with Metabolic syndrome treated with oral Eubacterium halliiMetabolic syndrome10018424NL-OMON44478Academisch Medisch Centrum27
已完成
不适用
Dosefinding trial studying effect of 4 weeks Intervention on safety and efficacy in males with Metabolic syndrome with oral Eubacterium halliimetabolic syndrome, obesity, insulin resistance, NAFLDNL-OMON22563AMC27
已完成
不适用
Efficacy trial of ingestion of the developmental code USRP-003JPRN-UMIN000033923Kao Corporation20
